Get all premium features to the best stock analysis tool

MediPharm Labs Reports Positive Q2 2026 Net Income and Second Consecutive Quarter of Positive Adjusted EBITDA

Q2 2026 Adjusted EBITDA1 of $0.9M, the Company's strongest quarterly performance since 20192 Positive net income in Q2 2026, compared with a net loss of $3.8M in Q2 2025 OPEX decreased 44% in Q2 2026 versus Q2 2025 Net Revenue of $10.0M, an increase of 11% versus Q1 2026 with German revenue increasing 45% sequentially and 33% year over year Cash of $9.9M consistent with Q1 2026, and the Company remains virtually debt free, with outright ownership of two production facilities appraised at over $15M Positive Phase II LiBBY trial results presented demonstrating statistically significant improvement in agitation symptoms using MediPharm's proprietary cannabinoid formulation Management to Host Conference Call / Webcast on August 13th, 2026, at 10:00 am ET TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, today announced its financial results for the three and six months ended June 30, 2026 ("Q2 2026"). The Company improved sequentially on revenue, gross margin and Adjusted EBITDA versus the three months ended March 31, 2026 ("Q1 2026").